Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer
ConclusionMMR protein andMLH1 methylation status predict the response to adjuvant therapy in endometrial cancer. The MMR system could be utilized for selection of patients who most likely benefit from adjuvant therapy. (Source: Cancer Medicine)
Source: Cancer Medicine - January 15, 2021 Category: Cancer & Oncology Authors: Mikko Loukovaara, Annukka Pasanen, Ralf B ützow Tags: ORIGINAL RESEARCH Source Type: research

Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study
The objective of this prospective observational study was to estimate, based on intensive screening, using computed tomography, lower ‐extremity ultrasonography, and D‐dimer testing, the prevalence of VTE in patients with advanced cancer.Patients with metastatic or locally advanced cancer without anticoagulant therapy, who were planning to receive chemotherapy during 4  weeks, were eligible. Evaluations of VTE were performed at pretreatment, 12 weeks, and 24 weeks after the start of chemotherapy. Primary endpoint was cumulative incidence of VTE for 24 weeks. Secondary endpoints included incidence of...
Source: Cancer Medicine - January 9, 2021 Category: Cancer & Oncology Authors: Hirotsugu Kenmotsu, Akifumi Notsu, Keita Mori, Shota Omori, Takahiro Tsushima, Yasuomi Satake, Yoshihiro Miki, Masakazu Abe, Masahito Ogiku, Toshio Nakamura, Masakazu Takagi, Hideto Ochiai, Hirofumi Yasui, Toshiaki Takahashi Tags: ORIGINAL RESEARCH Source Type: research

Regional and temporal variation in receipt of long ‐term opioid therapy among older breast, colorectal, lung, and prostate cancer survivors in the United States
Our study examines the regional and temporal trends in receipt of long ‐term opioid therapy among older adults who have lived 5 or more years after cancer diagnosis. We found the annual trends in the receipt of long‐term opioid therapy were the highest in the south and lowest in the northeast. Variation in a clinical practice suggests the need for more research and interventions to improve efficiency, process, cost, and quality of care. AbstractBackgroundOlder cancer survivors have high rates of long ‐term opioid therapy (≥90 days/year). However, the geographical and temporal variation in long‐term opioid t...
Source: Cancer Medicine - January 9, 2021 Category: Cancer & Oncology Authors: Derrick C. Gibson, Mukaila A. Raji, Jacques G. Baillargeon, Yong ‐Fang Kuo Tags: ORIGINAL RESEARCH Source Type: research

OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer
Our study proved that the expression of OGDHL was closely related to the prognosis of PTC, and could be used as a new promising prognostic biomarker for PTC. AbstractBackgroundPapillary thyroid cancer (PTC) is the most common type of thyroid cancer. However, due to the lack of reliable prognostic biomarkers for PTC, overtreatment has been on the rise. Therefore, our research aims to identify new and promising prognostic biomarkers and provide fresh perspectives for clinical decision making.MethodsThe RNA ‐seq data and clinical data of PTC samples were obtained from The Cancer Genome Atlas data portal.GSE64912 andGSE83520...
Source: Cancer Medicine - January 6, 2021 Category: Cancer & Oncology Authors: Min Mao, Rong ‐zhi Huang, Jie Zheng, Hai‐qi Liang, Wen‐hui Huang, Jing Liu, Jie‐hua Li Tags: ORIGINAL RESEARCH Source Type: research

Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site
ConclusionsWe profiled different tumor site origin of MACUP patients and established prediction models. These features might be significant for clinicians to improve the probabilities of predicting the primary sites, and to decide subsequent treatment strategy. (Source: Cancer Medicine)
Source: Cancer Medicine - January 6, 2021 Category: Cancer & Oncology Authors: Xinrong Li, Yan Shao, Liqiang Sheng, Junquan Zhu, Zeming Wang, Kaibo Guo, Leitao Sun Tags: ORIGINAL RESEARCH Source Type: research

Prognostic significance of serum inflammation indexes in different Lauren classification of gastric cancer
AbstractBackgroundInflammatory indexes are considered to be potential prognostic biomarkers for patients with gastric cancer (GC). However, little evidence has defined the prognostic significance of inflammatory indexes for GC with different Lauren classification.MethodsA total of 852 patients with GC were randomly selected consecutively into intestinal type and diffuse/mixed type groups. Group bias was reduced by propensity score matching. The cutoff values of inflammatory indexes were analyzed by receiver operating characteristic curve. The Kaplan –Meier method and log‐rank test were used to analyze the overall s...
Source: Cancer Medicine - January 6, 2021 Category: Cancer & Oncology Authors: Xin Yin, Tianyi Fang, Yimin Wang, Yufei Wang, Daoxu zhang, Chunfeng Li, Yingwei Xue Tags: ORIGINAL RESEARCH Source Type: research

The effect of anticancer treatment on cancer patients with COVID ‐19: A systematic review and meta‐analysis
No significant difference was seen in any anticancer treatments in solid tumor subgroup. Chemotherapy, however, will lead to a higher mortality in patients with hematological malignancies. AbstractBackgroundThe relationship between cancer and COVID ‐19 has been revealed during the pandemic. Some anticancer treatments have been reported to have negative influences on COVID‐19‐infected patients while other studies did not support this hypothesis.MethodsA literature search was conducted in WOS, PubMed, Embase, Cochrane Library, CNKI and VIP between Dec 1, 2019 and Sept 23, 2020 for studies on anticancer treatments ...
Source: Cancer Medicine - December 31, 2020 Category: Cancer & Oncology Authors: Hanqing Liu, Dan Yang, Xinyue Chen, Zhihong Sun, Yutong Zou, Chuang Chen, Shengrong Sun Tags: REVIEW Source Type: research

Circulating CEA ‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer
This study aims to clarify the significance of epithelial cell adhesion molecules (EpCAMs) and carcinoembryonic antigen (CEA) expressing circulating tumor cells (CTCs) in patients with gastric cancer. The number of EpCAM −CEA+ cells was significantly associated with recurrence free survival. Thus, we conclude that CEA‐positive CTCs will be a clinically beneficial biomarker in patients with gastric cancer. AbstractIt has been reported that circulating tumor cells (CTCs) are beneficial for predicting tumor stage or treatment response. Although epithelial cell adhesion molecules (EpCAMs) and cytokeratin (CK) have been...
Source: Cancer Medicine - December 31, 2020 Category: Cancer & Oncology Authors: Yuichiro Miki, Masakazu Yashiro, Kenji Kuroda, Tomohisa Okuno, Shingo Togano, Go Masuda, Hiroaki Kasashima, Masaichi Ohira Tags: ORIGINAL RESEARCH Source Type: research

Role of CD19 and specific KIT ‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities
We refined heterogeneous factors predicting clinical outcome in t(8;21) AML patients under induction with different cytarabine intensities.The specific KIT ‐D816 (rather than general KITmut) is more associated with response, EFS, and OS under standard‐dose Ara‐C induction, and induction chemotherapy containing intermediate‐dose Ara‐C abrogates response disadvantage caused by KIT‐D816.Combination of CD19 and KIT can deliver a more explicit r isk stratification profile and elaborately guide an individually risk‐adapted treatment strategy in t(8;21) AML. AbstractHigh ‐dose cytarabine (Ara‐C) has been reporte...
Source: Cancer Medicine - December 31, 2020 Category: Cancer & Oncology Authors: Biao Wang, Bin Yang, Yun Ling, Jihong Zhang, Xiaoying Hua, Weiying Gu, Feng Yan Tags: ORIGINAL RESEARCH Source Type: research

Relmacabtagene autoleucel (relma ‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
ConclusionsRelma ‐cel met the primary endpoint analysis and demonstrated a high rate of durable responses and low rate of CAR‐T‐associated toxicities in patients with r/r LBCL in a multicenter trial supporting regulatory submission in China. (Source: Cancer Medicine)
Source: Cancer Medicine - December 31, 2020 Category: Cancer & Oncology Authors: Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Daobin Zhou, Zhao Wang, Mingzhi Zhang, Jianqiu Wu, Hui Liu, Pian Zhang, Su Yang, Zisong Zhou, Hongxia Zheng, Yuqin Song, Jun Zhu Tags: ORIGINAL RESEARCH Source Type: research

A phase II trial of durvalumab and tremelimumab in metastatic, non ‐urothelial carcinoma of the urinary tract
ConclusionsIn a poor prognosis cohort of patients with non ‐UC, durvalumab and tremelimumab lacked clinical activity while demonstrating a manageable safety profile. (Source: Cancer Medicine)
Source: Cancer Medicine - December 31, 2020 Category: Cancer & Oncology Authors: Michal Sarfaty, Karissa Whiting, Min Yuen Teo, Chung ‐Han Lee, Vanessa Peters, Jennifer Durocher, Ashley M. Regazzi, Asia S. McCoy, Grace Hettich, Achim A. Jungbluth, Hikmat Al‐Ahmadie, Irina Ostrovnaya, Joshua Chaim, Dean F. Bajorin, Jo Tags: ORIGINAL RESEARCH Source Type: research

Issue Information
Cancer Medicine, Volume 9, Issue 24, Page 9179-9180, December 2020. (Source: Cancer Medicine)
Source: Cancer Medicine - December 31, 2020 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

Home ‐based chemotherapy for stage III colon cancer patients in Thailand: Cost‐utility and budget impact analyses
This study takes a so cietal perspective while conducting the cost‐utility and budget impact analyses (BIA) of HC and IP with an mFOLFOX6 regimen on patients with stage III colon cancer. We conducted a cost‐utility analysis with a 6‐month time horizon. The parameter inputs for the model were gathered from a retrosp ective cohort study on patients diagnosed with stage III colon cancer at Ramathibodi Hospital, Bangkok. The resource usage of HC and IP was determined based on medical records. The per‐unit direct medical, home health service, and adverse events (AE) management costs were gathered from the standar d cost...
Source: Cancer Medicine - December 30, 2020 Category: Cancer & Oncology Authors: Nattanichcha Kulthanachairojana, Phichai Chansriwong, Nintita Sripaiboonkij Thokanit, Suwannee Sirilerttrakul, Nopakan Wannakansophon, Suthira Taychakhoonavudh Tags: ORIGINAL RESEARCH Source Type: research

Long ‐term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma
ConclusionsDynamic changes in plasma EBV DNA pre ‐ and posttreatment could predict the long‐term survival outcome and provide accurate risk stratification in NPC. (Source: Cancer Medicine)
Source: Cancer Medicine - December 30, 2020 Category: Cancer & Oncology Authors: Wanxia Li, Jing Chen, Bijun Liang, Zonghua Li, Junzheng Li, Xiaofei Yuan, Shuting Wu, Fangfang Zeng, Xinyu Peng, Yanfei Li, Juan Lu, Feipeng Zhao, Xiong Liu Tags: ORIGINAL RESEARCH Source Type: research

Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
ConclusionsThe assessment of gland formation and neutrophil infiltration on routine histological sections can aid in prognostication and allow inferences to be made about molecular subtype, which may help guide patient management decisions and contribute to our understanding of heterogeneity in treatment response. (Source: Cancer Medicine)
Source: Cancer Medicine - December 28, 2020 Category: Cancer & Oncology Authors: Julia R. Naso, James T. Topham, Joanna M. Karasinska, Michael K.C. Lee, Steve E. Kalloger, Hui ‐li Wong, Jessica Nelson, Richard A. Moore, Andrew J. Mungall, Steven J.M. Jones, Janessa Laskin, Marco A. Marra, Daniel J. Renouf, David F. Scha Tags: ORIGINAL RESEARCH Source Type: research

Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy ‐induced nausea and vomiting: A prospective cohort study
For patients with elevated substance P level, NK1 ‐RA (NK1 receptor antagonist, aprepitant) could be used, although these patients receive moderate emetic risk chemotherapy. This could improve the quality of life of patients receiving chemotherapy, and chemotherapy without dose reduction might have chance to improve treatment outcome for these pa tients. AbstractChemotherapy ‐induced nausea and vomiting (CINV) is an unbearable side effect. Identifying high emetic risk patients and providing more active antiemetics strategies are mandatory to improve the tolerability of chemotherapy. In this prospective cohort study, le...
Source: Cancer Medicine - December 27, 2020 Category: Cancer & Oncology Authors: Hyung Soon Park, Hye Sung Won, Ho Jung An, Sung Shim Cho, Hyun Ho Kim, Der Sheng Sun, Yoon Ho Ko, Byoung Yong Shim Tags: ORIGINAL RESEARCH Source Type: research

A new cytokine ‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia
Here we report on the impact of the peripheral levels of two cytokines, the Fms ‐like tyrosine kinase 3 ligand (FL), and interleukin‐6 (IL‐6), evaluated during first‐line intensive induction. Indeed, a new risk stratification can be proposed, which supersedes the ELN 2017 classification to predict survivals in AML patients by examining their profile during the induction phase. AbstractThe aim of this study was to assess the potential impact of the kinetics of serum levels of seven cytokines during induction in acute myeloid leukemia (AML) patients. Indeed, the role of cytokines, in the pathophysiology and response ...
Source: Cancer Medicine - December 25, 2020 Category: Cancer & Oncology Authors: Pierre Peterlin, Joelle Gaschet, Thierry Guillaume, Alice Garnier, Marion Eveillard, Amandine Le Bourgeois, Michel Cherel, Camille Debord, Yannick Le Bris, Olivier Theisen, Catherine Godon, B éatrice Mahé, Viviane Dubruille, Soraya Wuilleme Tags: ORIGINAL RESEARCH Source Type: research

Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
In this review, we discuss the dual role of gut microbiome in triggering GI cancers, its association with host immunity and its beneficial functions in modulation of cancer immunotherapy responses. Furthermore, we consider the significance of gut microbiota as a potential biomarker for predicting the response to immunotherapy. AbstractThe human gastrointestinal (GI) tract harbors gut microbiome, which plays a crucial role in preserving homeostasis at the intestinal host ‐microbial interface. Conversely, specific gut microbiota may be altered during various pathological conditions and produce a number of toxic compounds a...
Source: Cancer Medicine - December 25, 2020 Category: Cancer & Oncology Authors: Sama Rezasoltani, Abbas Yadegar, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali Tags: REVIEW Source Type: research

Prevalence of Lynch syndrome in women with mismatch repair ‐deficient ovarian cancer
ConclusionsMost ovarian cancers with somatic MMR ‐D were confirmed to have LS in this cohort. Germline testing for LS in addition toBRCA1/2 for all women with an epithelial ovarian cancer would be efficient and would approach 100% sensitivity for identifying Lynch syndrome. Utilization of a multigene panel should also be considered, given the additional non ‐Lynch germline mutation identified in this cohort. (Source: Cancer Medicine)
Source: Cancer Medicine - December 25, 2020 Category: Cancer & Oncology Authors: Rachel Hodan, Kerry Kingham, Kristina Cotter, Ann K. Folkins, Allison W. Kurian, James M. Ford, Teri Longacre Tags: ORIGINAL RESEARCH Source Type: research

Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer
ConclusionsOur findings suggest class I HDAC inhibition can promote activation of intratumoral CD8 T cells, potentially by compromising suppressive networks within the EOC tumor microenvironment. In this manner, class I HDAC inhibition might render advanced ‐stage EOC susceptible to immunotherapeutic treatment modalities. (Source: Cancer Medicine)
Source: Cancer Medicine - December 24, 2020 Category: Cancer & Oncology Authors: Tyler R. McCaw, Nidhi Goel, Dewey J. Brooke, Ashwini A. Katre, Angelina I. Londo ño, Haller J. Smith, Troy D. Randall, Rebecca C. Arend Tags: ORIGINAL RESEARCH Source Type: research

New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review
Conclusion: Blood glucose management may allow physicians to intervene early and improve outcomes among patients with cancer. (Source: Cancer Medicine)
Source: Cancer Medicine - December 23, 2020 Category: Cancer & Oncology Authors: Ara Jo, Lisa Scarton, LaToya J. O'Neal, Samantha Larson, Nancy Schafer, Thomas J. George, Juan M. Munoz Pena Tags: REVIEW Source Type: research

Patient ‐derived scaffolds as a model of colorectal cancer
ConclusionsThe colorectal PDS model can be used as a simplified personalized tool that can potentially reveal important diagnostic and pathophysiological information related to the TME. (Source: Cancer Medicine)
Source: Cancer Medicine - December 23, 2020 Category: Cancer & Oncology Authors: Gabrielle T. Parkinson, Simona Salerno, Parmida Ranji, Joakim H åkansson, Yalda Bogestål, Yvonne Wettergren, Anders Ståhlberg, Elinor Bexe Lindskog, Göran Landberg Tags: ORIGINAL RESEARCH Source Type: research

Sequential CD19 and BCMA ‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
This study aims to investigate the safety and efficacy of sequential infusion of CD19‐CART and B‐cell maturation antigen (BCMA)‐CARTs for RRMM with a similar 3 + 3 dose escalation combined with a toxicity sentinel design. We enrolled 10 patien ts, among whom 7 received autologous infusion and 3 received allogeneic infusion. The median follow‐up time was 20 months. The most common grade 3/4 treatment‐emergent toxicities were hematological toxicities. Cytokine‐release syndrome (CRS) adverse reactions were grade 1/2 in 9 out of 10 sub jects. No dose‐limited toxicity (DLT) was observed for BCMA‐C...
Source: Cancer Medicine - December 23, 2020 Category: Cancer & Oncology Authors: Lingzhi Yan, Su Qu, Jingjing Shang, Xiaolan Shi, Liqing Kang, Nan Xu, Mingqing Zhu, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Guanghua Chen, Huirong Chang, Xiaming Zhu, Lei Yu, Depei Wu, Chengcheng Fu Tags: ORIGINAL RESEARCH Source Type: research

Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes
ConclusionHN and BT tumors of the pancreas displayed different mutational profiles, which had prognostic significances and indicated different potential therapeutic options. (Source: Cancer Medicine)
Source: Cancer Medicine - December 22, 2020 Category: Cancer & Oncology Authors: Junliang Lu, Ruoying Yu, Rui Liu, Xiaolong Liang, Jian Sun, Hui Zhang, Huanwen Wu, Zhiwen Zhang, Yang W. Shao, Junchao Guo, Zhiyong Liang Tags: ORIGINAL RESEARCH Source Type: research

Validation of International Working Group response criteria in higher ‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
In higher risk MDS patients responses associated with restoration of effective hematopoiesis namely complete remission (CR) are associated with better outcomes.Marrow CR without hematological improvement outside context of allogeneic hematopoietic stem cell transplant should not be included in response criteria assessing new therapeutic agents in MDS. AbstractThe utility of the International Working Group (IWG) 2006 response criteria for myelodysplastic syndromes (MDS) as a surrogate endpoint for outcomes is unclear. We assessed the validity of the IWG 2006 response criteria in a large cohort of higher ‐risk MDS patients...
Source: Cancer Medicine - December 22, 2020 Category: Cancer & Oncology Authors: Rami S. Komrokji, Najla H Al Ali, David Sallman, Eric Padron, Amy E. DeZern, John Barnard, Gail J. Roboz, Guillermo Garcia ‐Manero, Alan List, David P. Steensma, Mikkael A. Sekeres Tags: ORIGINAL RESEARCH Source Type: research

A clinical model to predict distant metastasis in patients with superficial gastric cancer with negative lymph node metastasis and a survival analysis for patients with metastasis
ConclusionsWe constructed a sensitive and discriminative nomogram to identify high ‐risk patients with SGC‐NLNM who may harbor dissemination at initial diagnosis. The tumor size and primary site were the largest contributors to DM prediction. Compared with radiotherapy, aggressive surgery, and chemotherapy may be better options for patients with DM. (Source: Cancer Medicine)
Source: Cancer Medicine - December 22, 2020 Category: Cancer & Oncology Authors: Jingyu Chen, Lunpo Wu, Zizhen Zhang, Sheng Zheng, Yifeng Lin, Ning Ding, Jiawei Sun, Liuhong Shi, Meng Xue Tags: ORIGINAL RESEARCH Source Type: research

Establishment and validation of a prognostic nomogram based on a novel five ‐DNA methylation signature for survival in endometrial cancer patients
This study aimed to explore the prognostic role of DNA methylation pattern in endometrial cancer (EC) patients.MethodsDifferentially methylated genes (DMGs) of EC patients with distinct survival from The Cancer Genome Atlas (TCGA) database were analyzed to identify methylated genes as biomarkers for EC prognosis. The Least Absolute Shrinkage and Selection Operator (LASSO) analysis was used to construct a risk score model. A nomogram was built based on analysis combining the risk score model with clinicopathological signatures together, and then verified in the validation cohort and patients in our own center.ResultsIn tota...
Source: Cancer Medicine - December 22, 2020 Category: Cancer & Oncology Authors: Xingchen Li, Fufen Yin, Yuan Fan, Yuan Cheng, Yangyang Dong, Jingyi Zhou, Zhiqi Wang, Xiaoping Li, Jianliu Wang Tags: ORIGINAL RESEARCH Source Type: research

Artificial neural networks for simultaneously predicting the risk of multiple co ‐occurring symptoms among patients with cancer
AbstractPatients with cancer often exhibit multiple co ‐occurring symptoms which can impact the type of treatment received, recovery, and long‐term health. We aim to simultaneously predict the risk of three symptoms: severe pain, moderate‐severe depression, and poor well‐being in order to flag patients who may benefit from pre‐emptive early sy mptom management. This was a retrospective population‐based cohort study of adults diagnosed with cancer between 2008 and 2015. We developed and tested an Artificial Neural Network (ANN) model to predict the risk of multiple co‐occurring symptoms within 6 months af...
Source: Cancer Medicine - December 22, 2020 Category: Cancer & Oncology Authors: Wenhui Xuyi, Hsien Seow, Rinku Sutradhar Tags: ORIGINAL RESEARCH Source Type: research

Impact of human papillomaviruses (HPV) on recurrence rate and malignant progression of sinonasal papillomas
The impact of HPV infection on recurrences and malignant transformation of sinonasal papillomas is elucidated. HPV infection rate is significantly higher in recurrent papillomas than in non ‐recurrent and the highest in papillomas with malignant progression. Most frequent HPV subtypes are HPV 6 in benign recurrent tumors, and HPV 16, 45, and 66 in malignant tumors, along with HPV 90 which is currently described for the first time in sinonasal papillomas. The data suggest that HPV inf ection is a risk factor for tumor recurrences. Malignant progression seems to be supported by high‐risk HPV genotypes (i.e., 16, 45, 66, ...
Source: Cancer Medicine - December 22, 2020 Category: Cancer & Oncology Authors: Anja Paehler vor der Holte, Inger Fangk, Sabine Glombitza, Ludwig Wilkens, Hans J. Welkoborsky Tags: ORIGINAL RESEARCH Source Type: research

225Ac ‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
ConclusionsThere results suggest that the combination of225Ac ‐lintuzumab with venetoclax is a promising therapeutic strategy for the treatment of patients with venetoclax‐resistant AML.Clinical trial of this combination therapy (NCT03867682) is currently ongoing. (Source: Cancer Medicine)
Source: Cancer Medicine - December 21, 2020 Category: Cancer & Oncology Authors: Ravendra Garg, Kevin J. H. Allen, Wojciech Dawicki, Eileen M. Geoghegan, Dale L. Ludwig, Ekaterina Dadachova Tags: ORIGINAL RESEARCH Source Type: research

AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival
ConclusionsOur findings ultimately reveal the association of hyperdiploidy on survival in AL amyloidosis patients, including the high ‐risk cardiac AL population. (Source: Cancer Medicine)
Source: Cancer Medicine - December 21, 2020 Category: Cancer & Oncology Authors: Michael Ozga, Qiuhong Zhao, Don Benson, Patrick Elder, Nita Williams, Naresh Bumma, Ashley Rosko, Maria Chaudhry, Abdullah Khan, Srinivas Devarakonda, Rami Kahwash, Ajay Vallakati, Courtney Campbell, Samir V. Parikh, Salem Almaani, Jason Pr Tags: ORIGINAL RESEARCH Source Type: research

Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second ‐line chemotherapy
Chemotherapeutic efficacy did not differ between the groups. Grade 3 or 4 AEs within the first four cycles of treatment may be an effective predictor of treatment efficacy in mCRC patients administered VEGF inhibitors as second ‐line chemotherapy AbstractBackgroundThree vascular endothelial growth factor (VEGF) inhibitors, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second ‐line chemotherapy. The difference in outcome between the three drugs has not been evaluated. In contrast to epidermal growth factor receptor inhib...
Source: Cancer Medicine - December 21, 2020 Category: Cancer & Oncology Authors: Hiroki Osumi, Eiji Shinozaki, Akira Ooki, Takeru Wakatsuki, Daisaku Kamiimabeppu, Taro Sato, Izuma Nakayama, Mariko Ogura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi Tags: ORIGINAL RESEARCH Source Type: research

“3‐Day Surprise Question” to predict prognosis of advanced cancer patients with impending death: Multicenter prospective observational study
ConclusionsThe 3 ‐Day Surprise Question can be a useful screening tool to identify advanced cancer patients with impending death. (Source: Cancer Medicine)
Source: Cancer Medicine - December 21, 2020 Category: Cancer & Oncology Authors: Tomoo Ikari, Yusuke Hiratsuka, Takuhiro Yamaguchi, Isseki Maeda, Masanori Mori, Yu Uneno, Tomohiko Taniyama, Yosuke Matsuda, Kiyofumi Oya, Keita Tagami, Akira Inoue Tags: ORIGINAL RESEARCH Source Type: research

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation –positive relapsed/refractory acute myeloid leukemia
In patients withFLT3‐mutated relapsed/refractory acute myeloid leukemia, theFLT3 inhibitor gilteritinib induced deep molecular responses characterized byFLT3–internal tandem duplication (FLT3‐ITD) mutation clearance. Among patients who achieved morphologic remission with gilteritinib therapy,FLT3‐ITD mutation clearance was associated with a trend toward longer survival. AbstractThe FLT3 inhibitor gilteritinib has clinical activity in patients withFLT3‐mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML). The impact ofFLT3 mutation clearance and the achievement of composite complete remiss...
Source: Cancer Medicine - December 19, 2020 Category: Cancer & Oncology Authors: Jessica K. Altman, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci, Mark J. Levis Tags: ORIGINAL RESEARCH Source Type: research

Survival benefit from immunocheckpoint inhibitors in stage IV non ‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
This study included 42,512 patients with stage IV NSCLC; 11,810 patients with BMs and 30,702 patients without BMs. In univariate analysis, stage IV NSCLC patients with BMs treated with immunotherapy had a significantly longer OS than those without immunotherapy after propensity score matching (median OS: 12.8 vs 10.1 months, hazard ratio [HR]: 0.80, 95% confidence interval [CI]: 0.72–0.8 9,p 
Source: Cancer Medicine - December 19, 2020 Category: Cancer & Oncology Authors: Shinkichi Takamori, Takefumi Komiya, Emily Powell Tags: ORIGINAL RESEARCH Source Type: research

Metabolic response as assessed by 18F ‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
ConclusionBased on these data, FDG ‐PET does not appear to predict EFS in IR or HR‐RMS. It remains to be determined whether FDG‐PET has a role in predicting survival outcomes in other RMS subpopulations. (Source: Cancer Medicine)
Source: Cancer Medicine - December 19, 2020 Category: Cancer & Oncology Authors: Douglas J. Harrison, Yueh ‐Yun Chi, Jing Tian, Pooja Hingorani, Leo Mascarenhas, Geoffrey B. McCowage, Brenda J. Weigel, Rajkumar Venkatramani, Suzanne L. Wolden, Torunn I. Yock, David A. Rodeberg, Andrea A. Hayes‐Jordan, Lisa A. Teot, Sh Tags: ORIGINAL RESEARCH Source Type: research

Fermented and nonfermented soy foods and the risk of breast cancer in a Japanese population ‐based cohort study
ConclusionsOur analyses showed that fermented soy foods had no association with overall breast cancer but may be associated with decreased risk of nonlocalized breast cancer. (Source: Cancer Medicine)
Source: Cancer Medicine - December 19, 2020 Category: Cancer & Oncology Authors: Ritsuko Shirabe, Eiko Saito, Norie Sawada, Junko Ishihara, Ribeka Takachi, Sarah Krull Abe, Taichi Shimazu, Taiki Yamaji, Atsushi Goto, Motoki Iwasaki, Manami Inoue, Shoichiro Tsugane, JPHC Study Group Tags: ORIGINAL RESEARCH Source Type: research

Risk factors and their diagnostic values for ocular metastases in invasive ductal carcinoma
The study provided a new method in the preventive diagnosis of distant metastasis in breast cancer. Risk factors CA153, ApoA1, and Hb could be used in clinical practice to predict OM in patients with IDC. AbstractInvasive ductal carcinoma (IDC) is a major type of breast cancer. Ocular metastasis (OM) in IDC is rarely seen, but patients with OM often have a poor prognosis. Furthermore, OM is difficult to detect in the early stages by common imaging examinations. In the present study, we tried to figure out the risk factors of OM in IDC and evaluate their diagnostic values for early detection. There were 1192 IDC patients wh...
Source: Cancer Medicine - December 18, 2020 Category: Cancer & Oncology Authors: Rong ‐Bin Liang, Kang Yu, Jie‐Li Wu, Jia‐Xiang Liu, Qi Lin, Biao Li, Yu‐Qing Zhang, Qian‐Min Ge, Qiu‐Yu Li, Hui‐Ye Shu, Yi Shao Tags: ORIGINAL RESEARCH Source Type: research

Prognostic impacts of extracranial metastasis on non ‐small cell lung cancer with brain metastasis: A retrospective study based on surveillance, epidemiology, and end results database
This study was designed to investigate the prognostic value of the number and sites of extracranial metastasis (ECM) in NSCLC patients with BM. NSCLC patients with BM from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 were enrolled in analysis. Patients from 2010 to 2013 were included in the training set and those from 2014 to 2015 in the validation set. ECM sites among different subtypes of NSCLC were compared by Chi ‐square tests. Kaplan–Meier methods and Cox regression models were performed to analyze survival data. Competing‐risks analysis was used to predict cumulative inc...
Source: Cancer Medicine - December 16, 2020 Category: Cancer & Oncology Authors: Miao Wang, Qiuji Wu, Jun Zhang, Guizhen Qin, Tian Yang, Yixin Liu, Xulong Wang, Boyu Zhang, Yongchang Wei Tags: ORIGINAL RESEARCH Source Type: research

Surveillance for radiation ‐related late effects in childhood cancer survivors: The impact of using volumetric dosimetry
In this cross ‐sectional cohort study of 132 eligible childhood cancer survivors treated with radiation therapy, we utilized current Children's Oncology Group Long‐term Follow‐Up Guidelines to compare the recommended screening practices triggered by use of conventional radiation fields ("irradiated regions" ) versus the more precise approach of volumetric dosimetry. This figure shows the number of recommended screening practices per patient per decade of follow‐up, by volumetric dosimetry (VD) compared with irradiated regions (IR). Each scatter plot point represents one patient with the number of rec omme...
Source: Cancer Medicine - December 16, 2020 Category: Cancer & Oncology Authors: Sally Cohen ‐Cutler, Arthur Olch, Kenneth Wong, Jemily Malvar, Richard Sposto, Pierre Kobierski, Amit Sura, Louis S. Constine, David R. Freyer Tags: ORIGINAL RESEARCH Source Type: research

Prognostic significance of the preoperative systemic immune ‐inflammation index in patients with oral cavity squamous cell carcinoma treated with curative surgery and adjuvant therapy
The SII is defined as platelet  × neutrophil/lymphocyte counts. Increased SII values predict poor distant control and overall survival in patients with oral cancer treated with curative resection and adjuvant RT/CCRT. Owing to the higher risk of systemic failure in this patient group, a tight follow‐up surveillance schedule or adjuvant systemic treatment may be advisable pending independent confirmation of our data. AbstractObjectivesTo investigate the prognostic value of the preoperative systemic immune ‐inflammation index (SII) in patients with oral cavity squamous cell carcinoma (OC‐SCC) treated wi...
Source: Cancer Medicine - December 16, 2020 Category: Cancer & Oncology Authors: Sheng ‐Ping Hung, Pei‐Rung Chen, Tsung‐Ying Ho, Kai‐Ping Chang, Wen‐Chi Chou, Ching‐Hsin Lee, Yao‐Yu Wu, Po‐Jui Chen, Chia‐Hsin Lin, Yung‐Chih Chou, Kang‐Hsing Fan, Chien‐Yu Lin, Bing‐Shen Huang, Joseph Tung‐Chieh Tags: ORIGINAL RESEARCH Source Type: research

Incidence of gastrointestinal stromal tumor in Chinese urban population: A national population ‐based study
This study aimed to estimate the incidence of GIST in urban population from mainland China in 2016.MethodsUrban Employee Basic Medical Insurance (UEBMI) and Urban Residence Basic Medical Insurance (URBMI) in China were used. The denominator of incidence was the total person ‐years of insured individuals in 2016 in the database, covering approximately 0.43 billion individuals. The numerator was the number of incident GIST cases in 2016.ResultsThe crude incidence in 2016 was 0.40 per 100,000 person ‐years (95% CI, 0.06–1.03). Male incidence was higher than female incidence (0.44 vs. 0.36, rate ratio: 1.22,p 
Source: Cancer Medicine - December 15, 2020 Category: Cancer & Oncology Authors: Lu Xu, Yanpeng Ma, Shengfeng Wang, Jingnan Feng, Lili Liu, Jinxi Wang, Guozhen Liu, Dianrong Xiu, Wei Fu, Siyan Zhan, Tao Sun, Pei Gao Tags: ORIGINAL RESEARCH Source Type: research

Randomized phase II trial of S ‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
This study examined two regimens of chemotherapy in concurrent chemoradiation. Eligible patients with unresectable, radically irradible LA‐NSCLC were randomize d to either the SP (S‐1 and cisplatin) or DP (docetaxel and cisplatin) arms with concurrent thoracic radiotherapy of 60 Gy, comprising 2 Gy per daily fraction. The primary endpoint was the overall survival (OS) rate at 2 years (the 2‐year OS rate). From May 2011 to August 2014, 110 patients w ere enrolled. Of 106 eligible patients, the 2‐year OS rates were 79% (95% CI: 66%–88%) and 69% (95% CI: 55%–80%) the SP and DP arms, respecti...
Source: Cancer Medicine - December 15, 2020 Category: Cancer & Oncology Authors: Tsuneo Shimokawa, Kazuhiko Yamada, Hiroshi Tanaka, Kaoru Kubota, Yuichi Takiguchi, Kazuma Kishi, Haruhiro Saito, Yukio Hosomi, Terufumi Kato, Daijiro Harada, Sakiko Otani, Takashi Kasai, Yoichi Nakamura, Toshihiro Misumi, Takeharu Yamanaka, Tags: ORIGINAL RESEARCH Source Type: research

Capacity building for cancer prevention and early detection in the Ugandan primary healthcare facilities: Working toward reducing the unmet needs of cancer control services
ConclusionsIn Uganda, the unmet needs for cancer control services are enormous. However, building the capacity of primary healthcare workers to integrate prevention and early detection of cancer into primary health care based on low ‐cost options for low‐income countries could contribute to reducing the unmet needs of cancer prevention and early detection in Uganda. (Source: Cancer Medicine)
Source: Cancer Medicine - December 15, 2020 Category: Cancer & Oncology Authors: Alfred Jatho, Noleb M. Mugisha, James Kafeero, George Holoya, Fred Okuku, Nixon Niyonzima, Jackson Orem Tags: ORIGINAL RESEARCH Source Type: research

Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long ‐term multicenter cohort study
Overall patient survival rate was significantly higher in patients without cancer, whereas graft survival rate was significantly higher in those with cancer. The aggressiveness of immunosuppressant regimens or potent immunosuppressant use after kidney transplantation improved graft survival rate, while increasing cancer morbidity. The type of immunosuppressant was not associated with increased cancer morbidity. AbstractKidney transplantation is the most promising treatment to improve mortality and life quality in end ‐stage kidney disease; however, cancer remains a leading cause of death. Several factors including immuno...
Source: Cancer Medicine - December 14, 2020 Category: Cancer & Oncology Authors: Ryoichi Imamura, Shigeaki Nakazawa, Kazuaki Yamanaka, Yoichi Kakuta, Koichi Tsutahara, Ayumu Taniguchi, Masataka Kawamura, Taigo Kato, Toyofumi Abe, Motohide Uemura, Tetsuya Takao, Hidefumi Kishikawa, Norio Nonomura Tags: ORIGINAL RESEARCH Source Type: research

Exostosin1 as a novel prognostic and predictive biomarker for squamous cell lung carcinoma: A study based on bioinformatics analysis
In this study, we analyzed the association between expression ofEXT1 andEXT2 genes and survival in patients with LUSC using bioinformatics resources such as Oncomine and The Cancer Genome Atlas (TCGA) databases, the Gene Expression Profiling Interactive Analysis (GEPIA) server and Kaplan –Meier plotter. Furthermore, regulatory microRNAs (miRNAs) were predicted forEXT1 and used to establish a potential miRNA ‐messenger RNA (mRNA) regulation network for LUSC using the ENCORI platform. We observed thatEXT1 andEXT2 expression levels were higher in LUSC than those in normal tissues. However, onlyEXT1 expression was sign...
Source: Cancer Medicine - December 14, 2020 Category: Cancer & Oncology Authors: Disheng Wu, Chao Huo, Siyu Jiang, Yanxia Huang, Xuehong Fang, Jun Liu, Min Yang, Jianwei Ren, Bilian Xu, Yi Liu Tags: ORIGINAL RESEARCH Source Type: research

Sentinel lymph node biopsy in early stage cervical cancer: A meta ‐analysis
ConclusionsSentinel lymph node biopsy using a tracer with a high detection rate and ultrastaging is highly accurate and reliable when limited to seriously selected patients, with satisfactory bilateral lymph node mapping and where enough cases for learning curve optimization exist. Indocyanine green sentinel lymph node mapping seems to be a superior sentinel lymph node mapping technique compared to other methods at present. (Source: Cancer Medicine)
Source: Cancer Medicine - December 14, 2020 Category: Cancer & Oncology Authors: Xinyue Zhang, Bingting Bao, Sixue Wang, Mingyu Yi, Li Jiang, Xiaoling Fang Tags: ORIGINAL RESEARCH Source Type: research

Analyzing non ‐cancer causes of death of colorectal carcinoma patients in the US population for the years 2000–2016
ConclusionsThese findings could help modify and sharpen preventive measures and clinical management and raise physician's awareness to potential non ‐CRC death risk factors for CRC patients. (Source: Cancer Medicine)
Source: Cancer Medicine - December 13, 2020 Category: Cancer & Oncology Authors: Lili Lu, Li Ma, Xianbin Zhang, Christina Susanne Mullins, Michael Linnebacher Tags: ORIGINAL RESEARCH Source Type: research

Quantitative ultrasound radiomics in predicting recurrence for patients with node ‐positive head‐neck squamous cell carcinoma treated with radical radiotherapy
Quantitative ultrasound radiomics obtained before starting treatment was used to predict the outcomes in patients with head ‐neck squamous cell carcinoma treated with radical radiotherapy. A KNN classifier was able to predict the recurrence with an accuracy of 75%. AbstractThis prospective study was conducted to investigate the role of quantitative ultrasound (QUS) radiomics in predicting recurrence for patients with node ‐positive head‐neck squamous cell carcinoma (HNSCC) treated with radical radiotherapy (RT). The most prominent cervical lymph node (LN) was scanned with a clinical ultrasound device having central f...
Source: Cancer Medicine - December 13, 2020 Category: Cancer & Oncology Authors: Archya Dasgupta, Kashuf Fatima, Daniel DiCenzo, Divya Bhardwaj, Karina Quiaoit, Murtuza Saifuddin, Irene Karam, Ian Poon, Zain Husain, William T. Tran, Lakshmanan Sannachi, Gregory J. Czarnota Tags: ORIGINAL RESEARCH Source Type: research

Impact of screening and follow ‐up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC‐AIM microsimulation model
ConclusionsAssuming identical adenoma sensitivities for screening and follow ‐up/surveillance colonoscopies underestimate the potential benefits of stool‐based screening strategies. (Source: Cancer Medicine)
Source: Cancer Medicine - December 13, 2020 Category: Cancer & Oncology Authors: Deborah A. Fisher, Leila Saoud, Kristen Hassmiller Lich, A. Mark Fendrick, A. Burak Ozbay, Bijan J. Borah, Michael Matney, Marcus Parton, Paul J. Limburg Tags: ORIGINAL RESEARCH Source Type: research